Metabolomic Analyses in the Placebo-controlled, Randomized Double-blind, n-of-1 Trial of TJ-68 to Improve Muscle Cramps in Patients With Amyotrophic Lateral Sclerosis (P10-9.013)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research investigates the metabolomic profiles of ALS patients and how these relate to the severity of muscle cramps and the effects of TJ-68 treatment.
Placebo-controlled, randomized double-blind n-of-1 trial design
Participants included ALS patients experiencing muscle cramps
Metabolomic analyses were conducted to evaluate treatment effects
Identified specific metabolomic profiles associated with varying degrees of muscle cramp severity
Showed improvements in muscle cramp frequency with TJ-68 treatment compared to placebo
Statistical significance of findings was established within the study parameters

Randomized trial evaluates TJ-68 for improving muscle cramps in ALS patients, suggesting potential benefits.

To describe metabolomics characteristics of patients with ALS relative to muscle cramp severity and treatment with TJ-68.

No takes yet. Share an insight, caveat, or question.

Oskarsson et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share